Children with tumors that involve muscles or bones, whether they are benign tumors or malignant sarcomas (such as Ewing’s sarcoma, osteosarcoma, rhabdomyosarcoma, and others), require multidisciplinary care. This includes input from a variety of surgical and medical subspecialists. The Musculoskeletal Tumor Program at Johns Hopkins provides comprehensive, multidisciplinary care to all children diagnosed with a tumor in bone, soft tissue, or connective tissue.
Every child seen by the Johns Hopkins Musculoskeletal Tumor Program will have his or her case reviewed and discussed at our multidisciplinary Tumor Conference. This weekly conference is attended by subspecialists from the following groups:
- Pediatric Oncology
- Pediatric Surgery
- Orthopedic Oncology
- Radiation Oncology
- Medical Oncology
The care and management of each child is discussed in depth, allowing the group as a whole to formulate a comprehensive treatment plan tailored to address the child’s age, tumor type and location. This approach maximizes the chance of cure and minimizes the degree of long term side effects. The formulation of the treatment plan involves input from every discipline, including those who may not need to be directly involved in the child’s care, but whose insight and experience is valued and whose involvement may be required in the future.
Hear Dr. David Loeb Discuss Childhood Sarcomas
Research is an important part of providing state-of-the-art cancer care. The Musculoskeletal Tumor Program includes a robust translational research program, which involves laboratory research that leads to institutional clinical trials of innovative therapies for bone and soft tissue sarcomas. We also participate in clinical trials run by the Sarcoma Alliance for Research Through Collaboration (SARC), a consortium of sarcoma programs from across North America, and by the Children’s Oncology Group (COG). In addition, industry-sponsored trials and clinical trials run by The Pediatric Oncology Experimental Therapeutics Investigators’ Consortium (POETIC) ensure that in addition to standard therapies, almost every child treated within the Johns Hopkins Musculoskeletal Tumor Program will have the opportunity to participate in cutting edge clinical research.